康芝药业2024年实现营收4.73亿元 2025年一季度同比大幅减亏3861万元

Core Insights - The company reported a revenue of 473 million yuan for the year 2024, with a net profit attributable to shareholders of -216 million yuan, indicating a loss [1] - The net cash flow from operating activities increased by 1.08% year-on-year, reflecting improvements in sales collection management, inventory management, and overall resource optimization [1] - In the first quarter of 2025, the company achieved a revenue of 112 million yuan, with a net profit of -9.69 million yuan, representing a significant reduction in losses by 79.16% year-on-year [1] - The improvement in performance is attributed to a decrease in sales expenses, which led to a reduced net profit loss [1] - The net cash flow for the first quarter was 40.51 million yuan, an increase of 228.66% compared to the same period last year, driven by reduced sales expenses and funds received from the controlling shareholder [1]